nodes	percent_of_prediction	percent_of_DWPC	metapath
Fludarabine—Cytarabine—lymphatic system cancer	0.411	1	CrCtD
Fludarabine—POLA1—Cytarabine—lymphatic system cancer	0.118	0.438	CbGbCtD
Fludarabine—SLC29A1—Cytarabine—lymphatic system cancer	0.0784	0.291	CbGbCtD
Fludarabine—DCK—Cytarabine—lymphatic system cancer	0.0726	0.27	CbGbCtD
Fludarabine—Ribavirin—Cytarabine—lymphatic system cancer	0.035	0.13	CrCrCtD
Fludarabine—Regadenoson—Cytarabine—lymphatic system cancer	0.0326	0.122	CrCrCtD
Fludarabine—S-Adenosylmethionine—Cytarabine—lymphatic system cancer	0.0326	0.122	CrCrCtD
Fludarabine—Clofarabine—Cytarabine—lymphatic system cancer	0.0326	0.122	CrCrCtD
Fludarabine—Adenosine monophosphate—Cytarabine—lymphatic system cancer	0.0289	0.107	CrCrCtD
Fludarabine—Nelarabine—Cytarabine—lymphatic system cancer	0.0289	0.107	CrCrCtD
Fludarabine—Vidarabine—Cytarabine—lymphatic system cancer	0.0259	0.0966	CrCrCtD
Fludarabine—Adenosine—Cytarabine—lymphatic system cancer	0.0259	0.0966	CrCrCtD
Fludarabine—Azacitidine—Cytarabine—lymphatic system cancer	0.0259	0.0966	CrCrCtD
Fludarabine—Adenosine triphosphate—ALK—lymphatic system cancer	0.000922	1	CrCbGaD
Fludarabine—POLA1—Vinblastine—Vincristine—lymphatic system cancer	0.000644	0.596	CbGdCrCtD
Fludarabine—RRM1—Azacitidine—Cytarabine—lymphatic system cancer	0.000436	0.404	CbGdCrCtD
Fludarabine—Haematuria—Bleomycin—lymphatic system cancer	0.000108	0.00216	CcSEcCtD
Fludarabine—Pruritus—Mechlorethamine—lymphatic system cancer	0.000107	0.00216	CcSEcCtD
Fludarabine—Anorexia—Teniposide—lymphatic system cancer	0.000106	0.00214	CcSEcCtD
Fludarabine—Pancytopenia—Carmustine—lymphatic system cancer	0.000105	0.00211	CcSEcCtD
Fludarabine—Diarrhoea—Mechlorethamine—lymphatic system cancer	0.000104	0.00208	CcSEcCtD
Fludarabine—Neutropenia—Carmustine—lymphatic system cancer	0.000103	0.00208	CcSEcCtD
Fludarabine—Haemoglobin—Bleomycin—lymphatic system cancer	0.000102	0.00205	CcSEcCtD
Fludarabine—Haemorrhage—Bleomycin—lymphatic system cancer	0.000101	0.00204	CcSEcCtD
Fludarabine—Hypoaesthesia—Bleomycin—lymphatic system cancer	0.000101	0.00203	CcSEcCtD
Fludarabine—Pancytopenia—Vincristine—lymphatic system cancer	0.0001	0.00201	CcSEcCtD
Fludarabine—Sweating increased—Mitoxantrone—lymphatic system cancer	0.0001	0.00201	CcSEcCtD
Fludarabine—Hyperglycaemia—Carmustine—lymphatic system cancer	9.96e-05	0.002	CcSEcCtD
Fludarabine—Dyspnoea—Teniposide—lymphatic system cancer	9.96e-05	0.002	CcSEcCtD
Fludarabine—Pneumonia—Carmustine—lymphatic system cancer	9.91e-05	0.00199	CcSEcCtD
Fludarabine—Dysuria—Vincristine—lymphatic system cancer	9.86e-05	0.00198	CcSEcCtD
Fludarabine—Neutropenia—Vincristine—lymphatic system cancer	9.86e-05	0.00198	CcSEcCtD
Fludarabine—Pancytopenia—Mitoxantrone—lymphatic system cancer	9.75e-05	0.00196	CcSEcCtD
Fludarabine—Decreased appetite—Teniposide—lymphatic system cancer	9.71e-05	0.00195	CcSEcCtD
Fludarabine—Renal failure—Carmustine—lymphatic system cancer	9.68e-05	0.00195	CcSEcCtD
Fludarabine—Neuropathy peripheral—Carmustine—lymphatic system cancer	9.65e-05	0.00194	CcSEcCtD
Fludarabine—Vomiting—Mechlorethamine—lymphatic system cancer	9.63e-05	0.00194	CcSEcCtD
Fludarabine—Neutropenia—Mitoxantrone—lymphatic system cancer	9.6e-05	0.00193	CcSEcCtD
Fludarabine—Stomatitis—Carmustine—lymphatic system cancer	9.6e-05	0.00193	CcSEcCtD
Fludarabine—Urinary tract infection—Carmustine—lymphatic system cancer	9.57e-05	0.00193	CcSEcCtD
Fludarabine—Rash—Mechlorethamine—lymphatic system cancer	9.55e-05	0.00192	CcSEcCtD
Fludarabine—Upper respiratory tract infection—Mitoxantrone—lymphatic system cancer	9.54e-05	0.00192	CcSEcCtD
Fludarabine—Dermatitis—Mechlorethamine—lymphatic system cancer	9.54e-05	0.00192	CcSEcCtD
Fludarabine—Pneumonia—Vincristine—lymphatic system cancer	9.46e-05	0.0019	CcSEcCtD
Fludarabine—Proteinuria—Methotrexate—lymphatic system cancer	9.28e-05	0.00187	CcSEcCtD
Fludarabine—Acute coronary syndrome—Vincristine—lymphatic system cancer	9.27e-05	0.00186	CcSEcCtD
Fludarabine—Hyperglycaemia—Mitoxantrone—lymphatic system cancer	9.26e-05	0.00186	CcSEcCtD
Fludarabine—Myocardial infarction—Vincristine—lymphatic system cancer	9.22e-05	0.00185	CcSEcCtD
Fludarabine—Neuropathy peripheral—Vincristine—lymphatic system cancer	9.22e-05	0.00185	CcSEcCtD
Fludarabine—Pneumonia—Mitoxantrone—lymphatic system cancer	9.21e-05	0.00185	CcSEcCtD
Fludarabine—Feeling abnormal—Teniposide—lymphatic system cancer	9.2e-05	0.00185	CcSEcCtD
Fludarabine—Stomatitis—Vincristine—lymphatic system cancer	9.16e-05	0.00184	CcSEcCtD
Fludarabine—Protein urine present—Methotrexate—lymphatic system cancer	9.15e-05	0.00184	CcSEcCtD
Fludarabine—Chills—Bleomycin—lymphatic system cancer	9.09e-05	0.00183	CcSEcCtD
Fludarabine—Acute coronary syndrome—Mitoxantrone—lymphatic system cancer	9.03e-05	0.00182	CcSEcCtD
Fludarabine—Renal failure—Mitoxantrone—lymphatic system cancer	9e-05	0.00181	CcSEcCtD
Fludarabine—Nausea—Mechlorethamine—lymphatic system cancer	9e-05	0.00181	CcSEcCtD
Fludarabine—Myocardial infarction—Mitoxantrone—lymphatic system cancer	8.98e-05	0.00181	CcSEcCtD
Fludarabine—Alopecia—Bleomycin—lymphatic system cancer	8.95e-05	0.0018	CcSEcCtD
Fludarabine—Stomatitis—Mitoxantrone—lymphatic system cancer	8.93e-05	0.0018	CcSEcCtD
Fludarabine—Urinary tract infection—Mitoxantrone—lymphatic system cancer	8.9e-05	0.00179	CcSEcCtD
Fludarabine—Haemoglobin—Carmustine—lymphatic system cancer	8.89e-05	0.00179	CcSEcCtD
Fludarabine—Haemorrhage—Carmustine—lymphatic system cancer	8.84e-05	0.00178	CcSEcCtD
Fludarabine—Body temperature increased—Teniposide—lymphatic system cancer	8.83e-05	0.00178	CcSEcCtD
Fludarabine—Hypoaesthesia—Carmustine—lymphatic system cancer	8.8e-05	0.00177	CcSEcCtD
Fludarabine—Hyperuricaemia—Methotrexate—lymphatic system cancer	8.79e-05	0.00177	CcSEcCtD
Fludarabine—Haematuria—Mitoxantrone—lymphatic system cancer	8.73e-05	0.00176	CcSEcCtD
Fludarabine—Sinusitis—Mitoxantrone—lymphatic system cancer	8.59e-05	0.00173	CcSEcCtD
Fludarabine—Visual impairment—Carmustine—lymphatic system cancer	8.52e-05	0.00171	CcSEcCtD
Fludarabine—Hypoaesthesia—Vincristine—lymphatic system cancer	8.4e-05	0.00169	CcSEcCtD
Fludarabine—Respiratory failure—Methotrexate—lymphatic system cancer	8.3e-05	0.00167	CcSEcCtD
Fludarabine—Blood uric acid increased—Methotrexate—lymphatic system cancer	8.3e-05	0.00167	CcSEcCtD
Fludarabine—Haemoglobin—Mitoxantrone—lymphatic system cancer	8.26e-05	0.00166	CcSEcCtD
Fludarabine—Hypersensitivity—Teniposide—lymphatic system cancer	8.23e-05	0.00166	CcSEcCtD
Fludarabine—Haemorrhage—Mitoxantrone—lymphatic system cancer	8.22e-05	0.00165	CcSEcCtD
Fludarabine—Ill-defined disorder—Bleomycin—lymphatic system cancer	8.18e-05	0.00165	CcSEcCtD
Fludarabine—Pharyngitis—Mitoxantrone—lymphatic system cancer	8.16e-05	0.00164	CcSEcCtD
Fludarabine—Anaemia—Bleomycin—lymphatic system cancer	8.15e-05	0.00164	CcSEcCtD
Fludarabine—Asthenia—Teniposide—lymphatic system cancer	8.01e-05	0.00161	CcSEcCtD
Fludarabine—Malaise—Bleomycin—lymphatic system cancer	7.95e-05	0.0016	CcSEcCtD
Fludarabine—Pruritus—Teniposide—lymphatic system cancer	7.9e-05	0.00159	CcSEcCtD
Fludarabine—Arrhythmia—Carmustine—lymphatic system cancer	7.9e-05	0.00159	CcSEcCtD
Fludarabine—Leukopenia—Bleomycin—lymphatic system cancer	7.89e-05	0.00159	CcSEcCtD
Fludarabine—Alopecia—Carmustine—lymphatic system cancer	7.81e-05	0.00157	CcSEcCtD
Fludarabine—Malnutrition—Carmustine—lymphatic system cancer	7.7e-05	0.00155	CcSEcCtD
Fludarabine—Cough—Bleomycin—lymphatic system cancer	7.69e-05	0.00155	CcSEcCtD
Fludarabine—Diarrhoea—Teniposide—lymphatic system cancer	7.64e-05	0.00154	CcSEcCtD
Fludarabine—Myalgia—Bleomycin—lymphatic system cancer	7.51e-05	0.00151	CcSEcCtD
Fludarabine—Alopecia—Vincristine—lymphatic system cancer	7.46e-05	0.0015	CcSEcCtD
Fludarabine—Coma—Methotrexate—lymphatic system cancer	7.45e-05	0.0015	CcSEcCtD
Fludarabine—Discomfort—Bleomycin—lymphatic system cancer	7.42e-05	0.00149	CcSEcCtD
Fludarabine—Chills—Mitoxantrone—lymphatic system cancer	7.38e-05	0.00148	CcSEcCtD
Fludarabine—Arrhythmia—Mitoxantrone—lymphatic system cancer	7.34e-05	0.00148	CcSEcCtD
Fludarabine—Alopecia—Mitoxantrone—lymphatic system cancer	7.26e-05	0.00146	CcSEcCtD
Fludarabine—Confusional state—Bleomycin—lymphatic system cancer	7.26e-05	0.00146	CcSEcCtD
Fludarabine—Oedema—Bleomycin—lymphatic system cancer	7.2e-05	0.00145	CcSEcCtD
Fludarabine—Anaphylactic shock—Bleomycin—lymphatic system cancer	7.2e-05	0.00145	CcSEcCtD
Fludarabine—Infection—Bleomycin—lymphatic system cancer	7.15e-05	0.00144	CcSEcCtD
Fludarabine—Anaemia—Carmustine—lymphatic system cancer	7.11e-05	0.00143	CcSEcCtD
Fludarabine—Vomiting—Teniposide—lymphatic system cancer	7.1e-05	0.00143	CcSEcCtD
Fludarabine—Agitation—Carmustine—lymphatic system cancer	7.07e-05	0.00142	CcSEcCtD
Fludarabine—Thrombocytopenia—Bleomycin—lymphatic system cancer	7.05e-05	0.00142	CcSEcCtD
Fludarabine—Rash—Teniposide—lymphatic system cancer	7.04e-05	0.00142	CcSEcCtD
Fludarabine—Dermatitis—Teniposide—lymphatic system cancer	7.03e-05	0.00142	CcSEcCtD
Fludarabine—Headache—Teniposide—lymphatic system cancer	7e-05	0.00141	CcSEcCtD
Fludarabine—Leukopenia—Carmustine—lymphatic system cancer	6.89e-05	0.00139	CcSEcCtD
Fludarabine—Anorexia—Bleomycin—lymphatic system cancer	6.86e-05	0.00138	CcSEcCtD
Fludarabine—Anaemia—Vincristine—lymphatic system cancer	6.79e-05	0.00137	CcSEcCtD
Fludarabine—Agitation—Vincristine—lymphatic system cancer	6.75e-05	0.00136	CcSEcCtD
Fludarabine—Convulsion—Carmustine—lymphatic system cancer	6.67e-05	0.00134	CcSEcCtD
Fludarabine—Ill-defined disorder—Mitoxantrone—lymphatic system cancer	6.64e-05	0.00134	CcSEcCtD
Fludarabine—Nausea—Teniposide—lymphatic system cancer	6.63e-05	0.00133	CcSEcCtD
Fludarabine—Anaemia—Mitoxantrone—lymphatic system cancer	6.61e-05	0.00133	CcSEcCtD
Fludarabine—Hepatic failure—Methotrexate—lymphatic system cancer	6.59e-05	0.00133	CcSEcCtD
Fludarabine—Leukopenia—Vincristine—lymphatic system cancer	6.58e-05	0.00132	CcSEcCtD
Fludarabine—Musculoskeletal discomfort—Bleomycin—lymphatic system cancer	6.56e-05	0.00132	CcSEcCtD
Fludarabine—Myalgia—Carmustine—lymphatic system cancer	6.55e-05	0.00132	CcSEcCtD
Fludarabine—Paraesthesia—Bleomycin—lymphatic system cancer	6.46e-05	0.0013	CcSEcCtD
Fludarabine—Malaise—Mitoxantrone—lymphatic system cancer	6.45e-05	0.0013	CcSEcCtD
Fludarabine—Dyspnoea—Bleomycin—lymphatic system cancer	6.42e-05	0.00129	CcSEcCtD
Fludarabine—Leukopenia—Mitoxantrone—lymphatic system cancer	6.4e-05	0.00129	CcSEcCtD
Fludarabine—Convulsion—Vincristine—lymphatic system cancer	6.37e-05	0.00128	CcSEcCtD
Fludarabine—Confusional state—Carmustine—lymphatic system cancer	6.33e-05	0.00127	CcSEcCtD
Fludarabine—Oedema—Carmustine—lymphatic system cancer	6.28e-05	0.00126	CcSEcCtD
Fludarabine—Decreased appetite—Bleomycin—lymphatic system cancer	6.26e-05	0.00126	CcSEcCtD
Fludarabine—Myalgia—Vincristine—lymphatic system cancer	6.26e-05	0.00126	CcSEcCtD
Fludarabine—Visual disturbance—Methotrexate—lymphatic system cancer	6.25e-05	0.00126	CcSEcCtD
Fludarabine—Cough—Mitoxantrone—lymphatic system cancer	6.24e-05	0.00126	CcSEcCtD
Fludarabine—Infection—Carmustine—lymphatic system cancer	6.24e-05	0.00126	CcSEcCtD
Fludarabine—Convulsion—Mitoxantrone—lymphatic system cancer	6.2e-05	0.00125	CcSEcCtD
Fludarabine—Pain—Bleomycin—lymphatic system cancer	6.15e-05	0.00124	CcSEcCtD
Fludarabine—Thrombocytopenia—Carmustine—lymphatic system cancer	6.15e-05	0.00124	CcSEcCtD
Fludarabine—Myalgia—Mitoxantrone—lymphatic system cancer	6.09e-05	0.00123	CcSEcCtD
Fludarabine—Arthralgia—Mitoxantrone—lymphatic system cancer	6.09e-05	0.00123	CcSEcCtD
Fludarabine—Cerebrovascular accident—Methotrexate—lymphatic system cancer	6.04e-05	0.00122	CcSEcCtD
Fludarabine—Discomfort—Mitoxantrone—lymphatic system cancer	6.02e-05	0.00121	CcSEcCtD
Fludarabine—Oedema—Vincristine—lymphatic system cancer	6e-05	0.00121	CcSEcCtD
Fludarabine—Anaphylactic shock—Vincristine—lymphatic system cancer	6e-05	0.00121	CcSEcCtD
Fludarabine—Anorexia—Carmustine—lymphatic system cancer	5.99e-05	0.0012	CcSEcCtD
Fludarabine—Infection—Vincristine—lymphatic system cancer	5.96e-05	0.0012	CcSEcCtD
Fludarabine—Feeling abnormal—Bleomycin—lymphatic system cancer	5.93e-05	0.00119	CcSEcCtD
Fludarabine—Confusional state—Mitoxantrone—lymphatic system cancer	5.89e-05	0.00118	CcSEcCtD
Fludarabine—Nervous system disorder—Vincristine—lymphatic system cancer	5.88e-05	0.00118	CcSEcCtD
Fludarabine—Thrombocytopenia—Vincristine—lymphatic system cancer	5.87e-05	0.00118	CcSEcCtD
Fludarabine—Anaphylactic shock—Mitoxantrone—lymphatic system cancer	5.84e-05	0.00117	CcSEcCtD
Fludarabine—Oedema—Mitoxantrone—lymphatic system cancer	5.84e-05	0.00117	CcSEcCtD
Fludarabine—Infection—Mitoxantrone—lymphatic system cancer	5.8e-05	0.00117	CcSEcCtD
Fludarabine—Hyperhidrosis—Vincristine—lymphatic system cancer	5.8e-05	0.00117	CcSEcCtD
Fludarabine—Musculoskeletal discomfort—Carmustine—lymphatic system cancer	5.72e-05	0.00115	CcSEcCtD
Fludarabine—Thrombocytopenia—Mitoxantrone—lymphatic system cancer	5.72e-05	0.00115	CcSEcCtD
Fludarabine—Anorexia—Vincristine—lymphatic system cancer	5.72e-05	0.00115	CcSEcCtD
Fludarabine—Body temperature increased—Bleomycin—lymphatic system cancer	5.69e-05	0.00114	CcSEcCtD
Fludarabine—Hyperhidrosis—Mitoxantrone—lymphatic system cancer	5.65e-05	0.00114	CcSEcCtD
Fludarabine—Paraesthesia—Carmustine—lymphatic system cancer	5.64e-05	0.00113	CcSEcCtD
Fludarabine—Dyspnoea—Carmustine—lymphatic system cancer	5.6e-05	0.00113	CcSEcCtD
Fludarabine—Anorexia—Mitoxantrone—lymphatic system cancer	5.57e-05	0.00112	CcSEcCtD
Fludarabine—Liver function test abnormal—Methotrexate—lymphatic system cancer	5.47e-05	0.0011	CcSEcCtD
Fludarabine—Musculoskeletal discomfort—Vincristine—lymphatic system cancer	5.46e-05	0.0011	CcSEcCtD
Fludarabine—Decreased appetite—Carmustine—lymphatic system cancer	5.46e-05	0.0011	CcSEcCtD
Fludarabine—Gastrointestinal disorder—Carmustine—lymphatic system cancer	5.42e-05	0.00109	CcSEcCtD
Fludarabine—Paraesthesia—Vincristine—lymphatic system cancer	5.38e-05	0.00108	CcSEcCtD
Fludarabine—Constipation—Carmustine—lymphatic system cancer	5.37e-05	0.00108	CcSEcCtD
Fludarabine—Pain—Carmustine—lymphatic system cancer	5.37e-05	0.00108	CcSEcCtD
Fludarabine—Toxic epidermal necrolysis—Methotrexate—lymphatic system cancer	5.33e-05	0.00107	CcSEcCtD
Fludarabine—Musculoskeletal discomfort—Mitoxantrone—lymphatic system cancer	5.32e-05	0.00107	CcSEcCtD
Fludarabine—Hypersensitivity—Bleomycin—lymphatic system cancer	5.3e-05	0.00107	CcSEcCtD
Fludarabine—Paraesthesia—Mitoxantrone—lymphatic system cancer	5.24e-05	0.00105	CcSEcCtD
Fludarabine—Decreased appetite—Vincristine—lymphatic system cancer	5.21e-05	0.00105	CcSEcCtD
Fludarabine—Dyspnoea—Mitoxantrone—lymphatic system cancer	5.21e-05	0.00105	CcSEcCtD
Fludarabine—Gastrointestinal disorder—Vincristine—lymphatic system cancer	5.18e-05	0.00104	CcSEcCtD
Fludarabine—Feeling abnormal—Carmustine—lymphatic system cancer	5.18e-05	0.00104	CcSEcCtD
Fludarabine—Fatigue—Vincristine—lymphatic system cancer	5.17e-05	0.00104	CcSEcCtD
Fludarabine—Asthenia—Bleomycin—lymphatic system cancer	5.16e-05	0.00104	CcSEcCtD
Fludarabine—Dyspepsia—Mitoxantrone—lymphatic system cancer	5.14e-05	0.00103	CcSEcCtD
Fludarabine—Constipation—Vincristine—lymphatic system cancer	5.13e-05	0.00103	CcSEcCtD
Fludarabine—Pain—Vincristine—lymphatic system cancer	5.13e-05	0.00103	CcSEcCtD
Fludarabine—Pruritus—Bleomycin—lymphatic system cancer	5.09e-05	0.00102	CcSEcCtD
Fludarabine—Decreased appetite—Mitoxantrone—lymphatic system cancer	5.08e-05	0.00102	CcSEcCtD
Fludarabine—Fatigue—Mitoxantrone—lymphatic system cancer	5.03e-05	0.00101	CcSEcCtD
Fludarabine—Pain—Mitoxantrone—lymphatic system cancer	4.99e-05	0.001	CcSEcCtD
Fludarabine—Constipation—Mitoxantrone—lymphatic system cancer	4.99e-05	0.001	CcSEcCtD
Fludarabine—Body temperature increased—Carmustine—lymphatic system cancer	4.97e-05	0.000999	CcSEcCtD
Fludarabine—Pancytopenia—Methotrexate—lymphatic system cancer	4.86e-05	0.000977	CcSEcCtD
Fludarabine—Feeling abnormal—Mitoxantrone—lymphatic system cancer	4.81e-05	0.000968	CcSEcCtD
Fludarabine—Dysuria—Methotrexate—lymphatic system cancer	4.78e-05	0.000962	CcSEcCtD
Fludarabine—Neutropenia—Methotrexate—lymphatic system cancer	4.78e-05	0.000962	CcSEcCtD
Fludarabine—Upper respiratory tract infection—Methotrexate—lymphatic system cancer	4.76e-05	0.000957	CcSEcCtD
Fludarabine—Body temperature increased—Vincristine—lymphatic system cancer	4.74e-05	0.000954	CcSEcCtD
Fludarabine—Hypersensitivity—Carmustine—lymphatic system cancer	4.63e-05	0.000931	CcSEcCtD
Fludarabine—Body temperature increased—Mitoxantrone—lymphatic system cancer	4.62e-05	0.000929	CcSEcCtD
Fludarabine—Pneumonia—Methotrexate—lymphatic system cancer	4.59e-05	0.000923	CcSEcCtD
Fludarabine—Vomiting—Bleomycin—lymphatic system cancer	4.58e-05	0.00092	CcSEcCtD
Fludarabine—Rash—Bleomycin—lymphatic system cancer	4.54e-05	0.000913	CcSEcCtD
Fludarabine—Dermatitis—Bleomycin—lymphatic system cancer	4.53e-05	0.000912	CcSEcCtD
Fludarabine—Stevens-Johnson syndrome—Methotrexate—lymphatic system cancer	4.52e-05	0.00091	CcSEcCtD
Fludarabine—Asthenia—Carmustine—lymphatic system cancer	4.51e-05	0.000907	CcSEcCtD
Fludarabine—Renal failure—Methotrexate—lymphatic system cancer	4.48e-05	0.000902	CcSEcCtD
Fludarabine—Stomatitis—Methotrexate—lymphatic system cancer	4.45e-05	0.000894	CcSEcCtD
Fludarabine—Hypersensitivity—Vincristine—lymphatic system cancer	4.42e-05	0.000889	CcSEcCtD
Fludarabine—Haematuria—Methotrexate—lymphatic system cancer	4.35e-05	0.000875	CcSEcCtD
Fludarabine—Epistaxis—Methotrexate—lymphatic system cancer	4.3e-05	0.000866	CcSEcCtD
Fludarabine—Hypersensitivity—Mitoxantrone—lymphatic system cancer	4.3e-05	0.000865	CcSEcCtD
Fludarabine—Asthenia—Vincristine—lymphatic system cancer	4.3e-05	0.000865	CcSEcCtD
Fludarabine—Diarrhoea—Carmustine—lymphatic system cancer	4.3e-05	0.000865	CcSEcCtD
Fludarabine—Nausea—Bleomycin—lymphatic system cancer	4.27e-05	0.00086	CcSEcCtD
Fludarabine—Asthenia—Mitoxantrone—lymphatic system cancer	4.19e-05	0.000843	CcSEcCtD
Fludarabine—Haemoglobin—Methotrexate—lymphatic system cancer	4.12e-05	0.000828	CcSEcCtD
Fludarabine—Diarrhoea—Vincristine—lymphatic system cancer	4.1e-05	0.000825	CcSEcCtD
Fludarabine—Haemorrhage—Methotrexate—lymphatic system cancer	4.1e-05	0.000824	CcSEcCtD
Fludarabine—Pharyngitis—Methotrexate—lymphatic system cancer	4.06e-05	0.000818	CcSEcCtD
Fludarabine—Diarrhoea—Mitoxantrone—lymphatic system cancer	4e-05	0.000804	CcSEcCtD
Fludarabine—Vomiting—Carmustine—lymphatic system cancer	3.99e-05	0.000803	CcSEcCtD
Fludarabine—Rash—Carmustine—lymphatic system cancer	3.96e-05	0.000797	CcSEcCtD
Fludarabine—Dermatitis—Carmustine—lymphatic system cancer	3.96e-05	0.000796	CcSEcCtD
Fludarabine—Visual impairment—Methotrexate—lymphatic system cancer	3.95e-05	0.000794	CcSEcCtD
Fludarabine—Headache—Carmustine—lymphatic system cancer	3.94e-05	0.000792	CcSEcCtD
Fludarabine—Erythema multiforme—Methotrexate—lymphatic system cancer	3.87e-05	0.000779	CcSEcCtD
Fludarabine—Vomiting—Vincristine—lymphatic system cancer	3.81e-05	0.000767	CcSEcCtD
Fludarabine—Rash—Vincristine—lymphatic system cancer	3.78e-05	0.000761	CcSEcCtD
Fludarabine—Dermatitis—Vincristine—lymphatic system cancer	3.78e-05	0.00076	CcSEcCtD
Fludarabine—Headache—Vincristine—lymphatic system cancer	3.76e-05	0.000756	CcSEcCtD
Fludarabine—Nausea—Carmustine—lymphatic system cancer	3.73e-05	0.000751	CcSEcCtD
Fludarabine—Vomiting—Mitoxantrone—lymphatic system cancer	3.71e-05	0.000747	CcSEcCtD
Fludarabine—Rash—Mitoxantrone—lymphatic system cancer	3.68e-05	0.000741	CcSEcCtD
Fludarabine—Dermatitis—Mitoxantrone—lymphatic system cancer	3.68e-05	0.00074	CcSEcCtD
Fludarabine—Chills—Methotrexate—lymphatic system cancer	3.67e-05	0.000739	CcSEcCtD
Fludarabine—Headache—Mitoxantrone—lymphatic system cancer	3.66e-05	0.000736	CcSEcCtD
Fludarabine—Alopecia—Methotrexate—lymphatic system cancer	3.62e-05	0.000728	CcSEcCtD
Fludarabine—Malnutrition—Methotrexate—lymphatic system cancer	3.57e-05	0.000717	CcSEcCtD
Fludarabine—Nausea—Vincristine—lymphatic system cancer	3.56e-05	0.000716	CcSEcCtD
Fludarabine—Nausea—Mitoxantrone—lymphatic system cancer	3.47e-05	0.000698	CcSEcCtD
Fludarabine—Ill-defined disorder—Methotrexate—lymphatic system cancer	3.31e-05	0.000665	CcSEcCtD
Fludarabine—Anaemia—Methotrexate—lymphatic system cancer	3.3e-05	0.000663	CcSEcCtD
Fludarabine—Malaise—Methotrexate—lymphatic system cancer	3.21e-05	0.000647	CcSEcCtD
Fludarabine—Leukopenia—Methotrexate—lymphatic system cancer	3.19e-05	0.000642	CcSEcCtD
Fludarabine—Cough—Methotrexate—lymphatic system cancer	3.11e-05	0.000626	CcSEcCtD
Fludarabine—Convulsion—Methotrexate—lymphatic system cancer	3.09e-05	0.000621	CcSEcCtD
Fludarabine—Myalgia—Methotrexate—lymphatic system cancer	3.04e-05	0.000611	CcSEcCtD
Fludarabine—Arthralgia—Methotrexate—lymphatic system cancer	3.04e-05	0.000611	CcSEcCtD
Fludarabine—Discomfort—Methotrexate—lymphatic system cancer	3e-05	0.000603	CcSEcCtD
Fludarabine—Confusional state—Methotrexate—lymphatic system cancer	2.93e-05	0.00059	CcSEcCtD
Fludarabine—Anaphylactic shock—Methotrexate—lymphatic system cancer	2.91e-05	0.000585	CcSEcCtD
Fludarabine—Infection—Methotrexate—lymphatic system cancer	2.89e-05	0.000581	CcSEcCtD
Fludarabine—Nervous system disorder—Methotrexate—lymphatic system cancer	2.85e-05	0.000574	CcSEcCtD
Fludarabine—Thrombocytopenia—Methotrexate—lymphatic system cancer	2.85e-05	0.000573	CcSEcCtD
Fludarabine—Hyperhidrosis—Methotrexate—lymphatic system cancer	2.81e-05	0.000566	CcSEcCtD
Fludarabine—Anorexia—Methotrexate—lymphatic system cancer	2.77e-05	0.000558	CcSEcCtD
Fludarabine—Musculoskeletal discomfort—Methotrexate—lymphatic system cancer	2.65e-05	0.000533	CcSEcCtD
Fludarabine—Paraesthesia—Methotrexate—lymphatic system cancer	2.61e-05	0.000526	CcSEcCtD
Fludarabine—Dyspnoea—Methotrexate—lymphatic system cancer	2.59e-05	0.000522	CcSEcCtD
Fludarabine—Dyspepsia—Methotrexate—lymphatic system cancer	2.56e-05	0.000515	CcSEcCtD
Fludarabine—Decreased appetite—Methotrexate—lymphatic system cancer	2.53e-05	0.000509	CcSEcCtD
Fludarabine—Gastrointestinal disorder—Methotrexate—lymphatic system cancer	2.51e-05	0.000505	CcSEcCtD
Fludarabine—Fatigue—Methotrexate—lymphatic system cancer	2.51e-05	0.000505	CcSEcCtD
Fludarabine—Pain—Methotrexate—lymphatic system cancer	2.49e-05	0.0005	CcSEcCtD
Fludarabine—Feeling abnormal—Methotrexate—lymphatic system cancer	2.4e-05	0.000482	CcSEcCtD
Fludarabine—Body temperature increased—Methotrexate—lymphatic system cancer	2.3e-05	0.000463	CcSEcCtD
Fludarabine—Hypersensitivity—Methotrexate—lymphatic system cancer	2.14e-05	0.000431	CcSEcCtD
Fludarabine—Asthenia—Methotrexate—lymphatic system cancer	2.09e-05	0.00042	CcSEcCtD
Fludarabine—Pruritus—Methotrexate—lymphatic system cancer	2.06e-05	0.000414	CcSEcCtD
Fludarabine—Diarrhoea—Methotrexate—lymphatic system cancer	1.99e-05	0.0004	CcSEcCtD
Fludarabine—Vomiting—Methotrexate—lymphatic system cancer	1.85e-05	0.000372	CcSEcCtD
Fludarabine—Rash—Methotrexate—lymphatic system cancer	1.83e-05	0.000369	CcSEcCtD
Fludarabine—Dermatitis—Methotrexate—lymphatic system cancer	1.83e-05	0.000369	CcSEcCtD
Fludarabine—Headache—Methotrexate—lymphatic system cancer	1.82e-05	0.000367	CcSEcCtD
Fludarabine—Nausea—Methotrexate—lymphatic system cancer	1.73e-05	0.000348	CcSEcCtD
